{"nctId":"NCT00463567","briefTitle":"26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2007-04"},"conditions":["Pulmonary Disease, Chronic Obstructive","COPD","Lung Diseases, Obstructive"],"count":2059,"armGroups":[{"label":"Indacaterol 150 µg (Continued Into Stage 2)","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to Indacaterol","Drug: Placebo to Formoterol"]},{"label":"Indacaterol 300 µg (Continued Into Stage 2)","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to Indacaterol","Drug: Placebo to Formoterol"]},{"label":"Tiotropium 18 µg (Continued Into Stage 2)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tiotropium (18 µg o.d.)"]},{"label":"Placebo (Continued Into Stage 2)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to Indacaterol","Drug: Placebo to Formoterol"]},{"label":"Indacaterol 75 µg (Not Continued into Stage 2)","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to Indacaterol","Drug: Placebo to Formoterol"]},{"label":"Indacaterol 600 µg (Not Continued Into Stage 2)","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to Formoterol"]},{"label":"Formoterol 12 µg (Not Continued Into Stage 2)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Formoterol (12 µg b.i.d.)","Drug: Placebo to Indacaterol"]}],"interventions":[{"name":"Indacaterol","otherNames":[]},{"name":"Formoterol (12 µg b.i.d.)","otherNames":[]},{"name":"Tiotropium (18 µg o.d.)","otherNames":[]},{"name":"Placebo to Indacaterol","otherNames":[]},{"name":"Placebo to Formoterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure\n* Co-operative outpatients with a diagnosis of COPD (moderate to severe as classified by the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) Guidelines, 2005) and:\n\n  * Smoking history of at least 20 pack years\n  * Post-bronchodilator FEV1 \\< 80% and ≥ 30% of the predicted normal value.\n  * Post-bronchodilator FEV1/FVC \\< 70% (Post refers to within 30 min of inhalation of 400 µg of salbutamol)\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period\n* Patients requiring long term oxygen therapy (\\> 15 h a day)\n* Patients who have had a respiratory tract infection 6 weeks prior to V1 (with further criteria)\n* Patients with concomitant pulmonary disease, pulmonary tuberculosis, or clinically significant bronchiectasis\n* Patients with a history of asthma (with further criteria)\n* Patients with Type I or uncontrolled Type II diabetes\n* Patients with contraindications for tiotropium\n* Patients who have clinically relevant laboratory abnormalities or a clinically significant abnormality\n* Any patient with active cancer or a history of cancer with less than 5 years disease free survival time\n* Patients with a history of long QT syndrome or whose QTc interval is prolonged\n* Patients with a hypersensitivity to any of the study drugs or drugs with similar chemical structures\n* Patients who have had treatment with the investigational drug (with further criteria)\n* Patients who have had live attenuated vaccinations within 30 days prior to visit 1, or during run-in period\n* Patients with known history of non compliance to medication\n* Patients unable to satisfactorily use a dry powder inhaler device or perform spirometry measurements\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 12 Weeks of Treatment","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":"0.015"},{"groupId":"OG001","value":"1.46","spread":"0.015"},{"groupId":"OG002","value":"1.42","spread":"0.015"},{"groupId":"OG003","value":"1.28","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"The Percentage of \"Days of Poor Control\" Reported Over the 26 Week Treatment Period","description":"A Chronic Obstructive Pulmonary Disease (COPD) \"day of poor control\" was defined as any day in the participant's diary with a score ≥2 (moderate or severe) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness). Score for each symptom ranges from 0-3; a higher number indicates a more severe symptom. The model contained baseline percentage of \"days of poor control\" as well as FEV1 reversibility components as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":"1.51"},{"groupId":"OG001","value":"30.8","spread":"1.51"},{"groupId":"OG002","value":"31.0","spread":"1.50"},{"groupId":"OG003","value":"34.0","spread":"1.53"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 2 Weeks of Treatment","description":"Interim Analysis: Stage 1.\n\nSpirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 h 10 min and the 23 h 45 min post dose values. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.49","spread":"0.024"},{"groupId":"OG001","value":"1.52","spread":"0.024"},{"groupId":"OG002","value":"1.45","spread":"0.023"},{"groupId":"OG003","value":"1.31","spread":"0.024"},{"groupId":"OG004","value":"1.46","spread":"0.024"},{"groupId":"OG005","value":"1.51","spread":"0.024"},{"groupId":"OG006","value":"1.42","spread":"0.024"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 1 Hour to 4 Hour Post Morning Dose After 2 Weeks of Treatment","description":"Interim Analysis: Stage 1.\n\nSpirometry was conducted according to internationally accepted standards. Standardized with respect to time (AUC 1h-4h) for FEV1 measurements taken from 1 hour to 4 hour post morning dose on Day 14. Standardized FEV1 AUC was calculated by the trapezoidal rule. Mixed model used baseline FEV1, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.53","spread":"0.034"},{"groupId":"OG001","value":"1.58","spread":"0.034"},{"groupId":"OG002","value":"1.49","spread":"0.034"},{"groupId":"OG003","value":"1.30","spread":"0.033"},{"groupId":"OG004","value":"1.50","spread":"0.034"},{"groupId":"OG005","value":"1.53","spread":"0.034"},{"groupId":"OG006","value":"1.52","spread":"0.035"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":416},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection","Cough","Headache"]}}}